|Articles|August 7, 2012
Mark Zitter, MBA, Discusses Oncology Pathways
Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs.
Advertisement
Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs. However, Zitter says that over the next year or so, pathways will not be the dominant factor in oncology management.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
2
TrumpRx Launch Brings Savings—and Uncertainty
3
Exploring Identity, Appearance Experiences Among Patients With Alopecia
4
5 Things to Know About the Oral GLP-1 Era
5
